Five things for pharma marketers to know: Friday, September 16, 2016

1. The FDA approved Aralez Pharmaceuticals' Yosprala, a pill that combines aspirin and omeprazole, which is used to treat heartburn and stomach ulcers. The combination is expected to protect patients who are already taking the combination of the two drugs against gastrointestinal side effects. (Reuters)  

2. Teva Pharmaceutical Industries is partnering with Intel to develop a wearable that will track the progression of Huntington's disease. Teva plans to incorporate the technology in an ongoing Phase-II study for a drug it is developing. (Reuters)

3. The New Mexico Attorney General sued Bristol-Myers Squibb and Sanofi for falsely marketing Plavix, their blood thinner. The attorney general alleges that the drugmakers knew the therapy didn't work for a significant percentage of patients. (Law360)

4. Both major-party presidential candidates have criticized drug-pricing practices, but neither has provided more than a few solutions to voters. There are several reasons why it's a challenge for the candidates to propose options, one of which is the numerous and often unrelated reasons that prompt drugmakers to raise the prices of their treatments. (Kaiser Health News)

5. ICYMI: Researchers say that men diagnosed with early prostate cancer who chose to closely monitor their disease are as likely to survive for at least another decade as those who undergo surgery or radiation. The study calls into question the need for any treatment for early-stage prostate cancers. (AP)